After spending $350 million in cash to lay its hands on rights to Nanjing-based Legend Biotech’s promising BCMA CAR-T LCAR-B38M (JNJ-68284528), the pharma giant will now hustle it into an FDA-approved Phase Ib/II trial for multiple myeloma with an eye to snagging an accelerated OK.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,